Oncotarget

Meta-Analysis:

CD147 expression was positively linked to aggressiveness and worse prognosis of gastric cancer: a meta and bioinformatics analysis

Hua-Chuan Zheng _ and Bao-Cheng Gong

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:90358-90370. https://doi.org/10.18632/oncotarget.20089

Metrics: PDF 687 views  |   HTML 1477 views  |   ?  


Abstract

Hua-Chuan Zheng1 and Bao-Cheng Gong1

1Department of Experimental Oncology and Animal Center, Shengjing Hospital of China Medical University, Shenyang 110004, China

Correspondence to:

Hua-Chuan Zheng, email: zheng_huachuan@hotmail.com

Keywords: CD147, gastric cancer, meta analysis, bioinformatics analysis

Received: June 01, 2017     Accepted: July 26, 2017     Published: August 09, 2017

ABSTRACT

CD147 (also named as Basigin or EMMPRIN) might promote cancer invasion and metastasis by inducing MMP and VEGF synthesis in tumor microenvironment. We performed a systematic meta and bioinformatics analysis through multiple online databases up to March 14, 2017. Up-regulated CD147 expression was found in gastric cancer, compared with normal mucosa (p < 0.05). The male patients with gastric cancer showed higher CD147 expression than the female ones (p < 0.0001). CD147 expression was positively correlated with tumor size, depth of invasion, lymph node metastasis, TNM staging and unfavorable prognosis of gastric cancer (p < 0.05). At mRNA level, CD147 expression was higher in intestinal-type and mixed-type gastric carcinomas than normal tissues (p < 0.05). CD147 mRNA expression was negatively associated with histological grading and dedifferentiation of gastric cancer (p < 0.05). A higher CD147 mRNA expression was negatively correlated with overall and progression-free survival rates of all cancer patients, even stratified by clinicopathological features (p < 0.05). These findings indicated that CD147 expression might be employed as a potential marker to indicate gastric carcinogenesis and subsequent progression, even prognosis.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 20089